Basic leucine zipper ATF-like transcription factor 3 (BATF3) (BATF3)

Basic leucine zipper ATF-like transcription factor 3 (BATF3) is a critical protein belonging to the AP-1 family that functions as a master regulator for the development of conventional type 1 dendritic cells (cDC1s). These specific dendritic cells are essential for the process of cross-presentation, where exogenous antigens (such as those from tumors or viruses) are processed and presented on MHC class I molecules to activate CD8+ cytotoxic T cells (PubMed: 22923514). Without BATF3, the immune system fails to mount effective CD8+ T cell-mediated anti-tumor responses, making this pathway a high-priority area in cancer immunotherapy (UniProt: P0C7M7). In the context of disease, BATF3-dependent cDC1s are frequently found to be excluded from the tumor microenvironment, which correlates with poor prognosis and resistance to checkpoint inhibitors. Therapeutic efforts currently center on indirect modulation, such as using Flt3 ligand (FLT3L) to expand the BATF3-dependent DC population or using TLR3 agonists to enhance their maturation and cross-priming efficiency (PubMed: 28506517). Direct targeting of BATF3 with small molecules remains a significant challenge due to its lack of a traditional ligand-binding pocket, but it remains a primary biomarker for identifying functional cross-presenting DC lineages in clinical research.

Other names

BATF3SNFTJDP1Jun dimerization protein 1B-ATF3Basic leucine zipper transcriptional factor ATF-like 3

Current therapeutic strategies focus on the expansion and activation of BATF3-dependent conventional type 1 dendritic cells (cDC1s) through FLT3L administration or TLR stimulation to enhance tumor antigen cross-presentation to CD8+ T cells.